Kevin F. McGee

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics

Peter S. Dragovich, Thomas J. Prins, Ru Zhou et al. · Journal of Medicinal Chemistry · 2003 · 113 citations

Pharmacotherapy, Antiviral Drug, Molecular Pharmacology +17

Discovery of (3<i>S</i>,3a<i>R</i>)-2-(3-Chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2<i>H</i>-benzo[<i>g</i>]indazole-7-carboxylic Acid (PF-3882845), an Orally Efficacious Mineralocorticoid Receptor (MR) Antagonist for Hypertension and Nephropathy

Marvin J. Meyers, Graciela B. Arhancet, Susan L. Hockerman et al. · Journal of Medicinal Chemistry · 2010 · 91 citations · Full text

Excellent Potency, Exquisite Potency, Renal Inflammation +19

Development of a Continuous Enzymatic Process for the Preparation of (<i>R</i>)-3-(4-Fluorophenyl)-2-hydroxy Propionic Acid

Junhua Tao, Kevin F. McGee · Organic Process Research & Development · 2002 · 57 citations

Engineering, Organic Chemistry, Chemistry +17

Lead Optimization toward Proof-of-Concept Tools for Huntington’s Disease within a 4-(1<i>H</i>-Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

John Wityak, Kevin F. McGee, Michael P. Conlon et al. · Journal of Medicinal Chemistry · 2015 · 38 citations

Molecular Biology, Pharmacotherapy, Proof-of-concept Tools +22

Fusicoccin Ring System by [4 + 4] Cycloaddition. Control of Diastereoselectivity through Hydrogen Bonding

Scott McN. Sieburth, Kevin F. McGee, Taleb H. Al‐Tel · Journal of the American Chemical Society · 1998 · 38 citations

Hydrogen Bondingscott Mcn, Engineering, Heterocyclic +15